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small molecule inhibitors that protect
human cells by blocking receptor binding
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activity.
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Clostridium difficile causes life-threatening diarrhea
through the actions of its homologous toxins TcdA
and TcdB on human colonocytes. Therapeutic
agents that block toxin-induced damage are urgently
needed to prevent the harmful consequences of
toxin action that are not addressed with current anti-
biotic-based treatments. Here, we developed an
imaging-based phenotypic screen to identify small
molecules that protected human cells from TcdB-
induced cell rounding. A series of structurally diverse
compounds with antitoxin activity were identified
and found to act through one of a small subset of
mechanisms, including direct binding and seques-
tration of TcdB, inhibition of endosomal maturation,
and noncompetitive inhibition of the toxin glucosyl-
transferase activity. Distinct classes of inhibitors
were used further to dissect the determinants of the
toxin-mediated necrosis phenotype occurring at
higher doses of toxin. These findings validate and
inform novel targeting strategies for discovering
small molecule agents to treat C. difficile infection.INTRODUCTION
Clostridium difficile is the leading cause of hospital-acquired in-
fectious diarrhea and antibiotic-associated pseudomembranous
colitis. C. difficile infections (CDIs) are almost always triggered
by alterations in the endogenous gastrointestinal flora in patients
taking broad-spectrum antibiotic treatments (Bartlett, 2002). The
current treatment strategies for patients with symptomatic
C. difficile are either to remove the offending antibiotic to
encourage reestablishment of healthy gut flora, or, contrariwise,
to administer additional antibiotics such as metronidazole,
vancomycin, and/or fidaxomicin to eradicate the pathogen
(Cohen et al., 2010; Venugopal and Johnson, 2012). Neither of
these approaches addresses the acute and chronic effects of
the secreted toxins on the gut during CDI. Moreover, increasing
treatment failure and relapse rates in patients, along with the
threat of resistance against current antibiotics, underscore theChemistry & Biology 22, 175need to search for therapies that neutralize toxin function (Kelly
and LaMont, 2008).
Pathogenic strains of C. difficile elaborate defined combina-
tions of two homologous toxins, TcdA and TcdB, and a binary
toxin called CDT. Extensive experimental and epidemiological
evidence indicates that TcdB and TcdA are the primary determi-
nants of virulence (Kuehne et al., 2010; Lyras et al., 2009), while
CDT appears to contribute to disease when present (Kuehne
et al., 2014). TcdA and TcdB are large four-domain toxins sharing
49% sequence identity and 63% sequence similarity (Figure 1A).
Both toxins enter cells by clathrin-mediated endocytosis (Papa-
theodorou et al., 2010), whereupon organelle acidification leads
to conformational changes that result in the creation of a trans-
membrane pore (Qa’dan et al., 2005; Zhang et al., 2014) and
delivery of the N-terminal autoprocessing cysteine protease
domain (CPD) and glucosyltransferase domains (GTD) into the
cytosol. Allosteric activation of the CPD by intracellular inositol
hexakisphosphate (IP6) induces release of the GTD into the
cytosol (Pruitt et al., 2009), which inactivates small Rho-family
GTPases involved in regulating actin dynamics (Just et al.,
1995a, 1995b). Inactivation of Rho proteins leads to the loss
of structural integrity of the cell as a consequence of F-actin
effects resulting from dysregulation of actin depolymerization
(Voth and Ballard, 2005). Loss of cell integrity and the conse-
quent cell rounding precede apoptosis and finally death of the
intoxicated cell, which is thought to occur via a caspase-3-
and caspase-9-dependent pathway (Hippenstiel et al., 2002).
Significantly, despite sharing similar structures and mechanisms
of cellular intoxication, TcdB is at least 100-fold more potent
than TcdA in its ability to induce cell rounding and apoptotic
cell death in various cell types (Chaves-Olarte et al., 1997; Donta
et al., 1982).
Functional studies using domain-inactivating mutants and
truncations have established that the cytopathic and cytotoxic
effects of toxins on cells require an enzymatically active GTD
and a pore formation competent delivery domain (Faust et al.,
1998; Genisyuerek et al., 2011; Hofmann et al., 1997; Jank
et al., 2007; Zhang et al., 2013, 2014). The CPD activity and
C-terminal CROPs domains, although important for full toxicity,
appear to not be essential for cellular intoxication, as inactivation
or removal of either domain yields toxin variants that are just 10-
to 100-fold less toxic to cells (Gerhard et al., 2013; Kreimeyer
et al., 2011; Li et al., 2013; Olling et al., 2011). Distinct from
the potent cytopathic/cytotoxic effects that are observed at
subpicomolar to low picomolar concentrations of TcdB, it was–185, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 175
Figure 1. A High-Throughput Phenotypic Screen of TcdB-Induced Cell-Rounding
(A) (Top) Schematic of the TcdB domain structure. DD, delivery domain; RBD, receptor binding domain. (Bottom) A cartoon depicting the stepwise mechanism of
target cell intoxication by TcdA and TcdB that leads to cell rounding (see Introduction for details).
(B) Representative images from wells of a 96-well plate of untreated (top) and TcdB-treated (bottom) IMR-90 cells 3 hr post treatment taken with a Cellomics
ArrayScan VTI reader using a 103 objective. Blue outlines denote the CellTracker-labeled cells identified by the target acquisition algorithm for the quantification
of cellular morphology.
(C) Quantification of changes in cell area, A, LWR, and (LWR 3 A), which we defined here as the CRI. Results ± SEM are the average of three independent
experiments.
(D) Titration of TcdB on human IMR-90 cells (n = 3; showing SEM) identifies a dose of toxin where 99% of cells were rounded; i.e., EC99 = 10 pM.
(E) High-throughput phenotypic screening data. Each square represents inhibition of cell rounding for a given compound tested at 40 mM. The dashed line
represents the calculated hit cutoff (3s = 39%). A histogram (right) shows the distribution of compounds (in 5% bins) with respect to inhibition of rounding.shown recently that higher concentrations of TcdB (i.e.,100- to
1,000-fold higher than required for cell rounding) induced
NADPH oxidase-mediated necrosis in target cells (Chumbler
et al., 2012; Farrow et al., 2013; Wohlan et al., 2014). Surpris-
ingly, this phenotype was found to be independent of both
CPD and GTD activity, depending primarily on a pore formation
competent delivery domain (Zhang et al., 2014), and presumably
an intact receptor binding moiety. Although the physiological
relevance of this phenotype remains to be validated, that the
concentrations required to induce this phenotype correlate
with pathology in a model of epithelial damage (Chumbler
et al., 2012) suggests that this phenotype may be important,
perhaps in fulminant infection, where much higher doses of toxin
may be reached.
In this study, we set out to identify therapeutic strategies to
neutralize the actions of TcdB on cells using chemical libraries
composed of diverse small molecules. With four potential toxin
domains and several host pathways and processes to target
(Figure 1A), the question arises: which targeting strategy is the
best? To address this, we used a chemical genetics strategy
that allowed us to probe all targets and pathways simultaneously176 Chemistry & Biology 22, 175–185, February 19, 2015 ª2015 Elseto identify the most drug-sensitive targets and nodes to target
using small molecules. Using this approach, we report the
identification of several small molecules capable of protecting
cells from TcdB-induced rounding, including toxin-modifying
compounds, a toxin-stabilizing molecule, inhibitors of endoso-
mal acidification, and noncompetitive inhibitors of GTD activity.
Using mechanistically distinct classes of inhibitors, we further
demonstrate distinct outcomes of targeting cell rounding versus
necrosis. These findings form the basis for linking the functional
importance of each domain and targeting step with respect to
a given phenotype and provide a foundation for developing the
first-generation inhibitors targeting the highly pathogenic toxins
of C. difficile.
RESULTS
Phenotypic HTS for Inhibitors of TcdB-Induced
Cell Rounding
To enable screening of chemical libraries, a robust high-
throughput assay of cell rounding was developed using a high-
content imaging platform that could track changes in severalvier Ltd All rights reserved
Figure 2. Neutralization of TcdB by Inhibition of Endosomal
Acidification
(A) Representative IMR-90 cell images untreated and treated with bafilo-
mycin A1.
(B) LysoTracker staining of acidic organelles (red puncta) is inhibited by
bafilomycin A1.
(C) Quantification of LysoTracker staining using the plate-based total fluo-
rescence measurement. Results ± SEM are the average of three independent
experiments.
(D) Comparison of the inhibition of LysoTracker staining (red) and cell rounding
(orange).
Chemistry & Biology 22, 175indices of cell morphology in response to TcdB treatment (Fig-
ure S1 available online). TcdB-induced changes to cell area
and the length to width ratio (LWR) were found to be the most
pronounced and statistically robust parameters (Figures 1B
and 1C). The product of these two parameters yielded what
we define here as the cell-rounding index (CRI), which gave
HTS-compatible Z0 factors >0.55 in either 96- or 384-well for-
mats. For screening, human-derived IMR-90 fibroblasts were
pretreated with compound (final concentration = 40 mM) for
10 min, followed by treatment with a concentration of TcdB
that resulted in 99% of cells becoming rounded after 3 hr at
37C (viz., EC99 = 10 pM; Figure 1D). A small molecule chemical
library consisting of natural products, drugs approved for human
use, and molecules with known biological activity was screened
(Figure 1E). In this screen, 66 compounds protected cells by
greater than three SDs above the library mean, corresponding
to an inhibition of CRI = 39%, of which 29 confirmed, yielding
an adjusted hit rate of 1.25%.
Nonselective Inhibitors of TcdB-Induced Cell Rounding
To identify and flag hits acting through nonspecific, promiscu-
ous, or otherwise undesirable mechanisms, we used general
filters to hits in addition to themore detailed studies. These filters
proved to be critical for correctly elucidating the mechanism of
action for certain hits and removing others. In particular, two
hits, epigallocatechin-3-monogallate (EGCG) and theaflavin
monogallate (TG), structural analogs from tea, were found
during initial characterization to inhibit TcdB glucosyltransferase
activity. We discovered, however, that small amounts of Triton
X-100 in the reaction mixture significantly reduced their potency,
hallmarks of a promiscuous aggregation mode of binding and
inhibition (Feng and Shoichet, 2006) (Figure S2). More dramati-
cally, we found that incubating TcdB with either EGCG or TG
resulted in the formation of TcdB aggregates that persisted on
SDS-PAGE. Moreover, using the unrelated human Rac-1
GTPase protein as a control, we observed a similar induction
of SDS-resistant aggregates (Figure S2).
Multiple Inhibitors of Endosomal Acidification Prevent
Toxin Translocation
Following uptake of TcdB, the cytotoxic GTD must be delivered
across the endosomal membrane. Endosomal acidification in-
duces conformational changes in TcdB that result in the creation
of a pore through which the GTD can pass (Zhang et al., 2014).
Agents that inhibit endosome-lysosome acidification, such as
the general v-ATPase inhibitor bafilomycin A1, or the lysosomo-
tropic weak base ammonium chloride, can therefore indirectly
neutralize TcdB toxicity by preventing pore formation and trans-
location (Qa’Dan et al., 2000). In the presence of bafilomycin A1,
cells were completely protected from TcdB-induced rounding
(Figure 2A).
To identify whether any hits protected cells from TcdB by
inhibiting endosomal acidification, we tested for their ability to
competitively reduce accumulation of the pH-sensitive fluores-
cent dye LysoTracker red within acidic organelles. Preincubation
of cells with bafilomycin A1 prior to addition of LysoTracker red
largely ablated endosomal/lysosomal staining as observed by
fluorescencemicroscopy (Figure 2B). Using a recently described
plate-based modification of this protocol (Slater et al., 2013), we–185, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 177
quantified LysoTracker staining in the presence of each hit
(Figure 2C). Among the hits that protected cells from TcdB intox-
ication, we found several that significantly inhibited LysoTracker
staining to levels similar to bafilomycin, including the carboxylic
ionophore monensin and a number of other compounds
with characteristic lysosomotropic features (i.e., weakly basic
amines), such as aminacrine, amodiaquine, quinacrine, and pra-
zosin (de Duve et al., 1974) (Figure 2C). Using the antimalarial
drug quinacrine (the most potent inhibitor of cell rounding), we
confirmed that the extent of inhibition of LysoTracker staining
tracked closely with the extent inhibition of TcdB-induced cell
rounding (Figure 2D).
Conformational Stabilization of TcdB by Methyl Cholate
Prevents Toxicity
A hit with a unique profile that was identified here was the bile
acid derivative methyl cholate. Of the 12 bile acid analogs that
were tested, methyl cholate was the most potent, and in fact
the only one that was identified as a hit in the primary screen
(Figure 3A). Notably, a number of close analogs of methyl
cholate with subtle changes in some cases were either only
partially active (i.e., methyldeoxycholate), or completely inactive
(i.e., cholic acid), suggesting a degree of specificity for methyl
cholate. Next, we tested the selectivity of methyl cholate for
TcdB over TcdA. Remarkably, we observed virtually no inhibi-
tion of TcdA-induced cell rounding over doses at which we
see complete protection of the more potent TcdB (Figure 3B).
Given this profile, we reasoned that methyl cholate was not
likely inhibiting a general host target or process common to
TcdA and TcdB, but rather likely interacting directly with
TcdB. To test this, we first tested the thermal stability of TcdB
in the absence and presence of increasing doses of methyl
cholate and cholic acid using differential scanning fluorimetry
(Niesen et al., 2007) (Figure 3C). Methyl cholate, and not cholic
acid, induced a robust increase in the thermal stability of TcdB;
the melting temperature (Tm) of TcdB dose dependently
increased from 49C in DMSO to 55C in the presence of methyl
cholate (Figure 3C). No change in stability was observed for
TcdA (data not shown).
To characterize the mechanism of methyl cholate neutraliza-
tion of TcdB further, we next assayed the relevant functions of
the individual toxin domains in the presence of methyl cholate.
The GTD, which catalyzes the transfer of a glucose moiety
from UDP-glucose to an Rac1-GTPase acceptor, was not in-
hibited by methyl cholate using the in vitro Western blot assay
(Figure 3D). By contrast, methyl cholate dose dependently
inhibited IP6-induced autoprocessing of full-length TcdB (Fig-
ure 3E). Unexpectedly, this inhibition was seen only in the
context of the holotoxin; no inhibition of autoprocessing by
methyl cholate was evident in a truncated construct (i.e., GTD-
CPD), indicating that the methyl cholate binding site was either
disrupted in the context of the truncation or was outside the
CPD (Figure 3E). Remarkably, when we tested the effect of
methyl cholate on receptor binding, we saw a dramatic decrease
in the amount of toxin bound to cells. Methyl cholate, but not
cholic acid, inhibited TcdB binding to cells to a similar extent
to the neutralizing monoclonal antibody bezlotoxumab (Orth
et al., 2014) (Figure 3F). These data indicate that methyl cholate
binds at a site unique to TcdB and induces a conformational178 Chemistry & Biology 22, 175–185, February 19, 2015 ª2015 Elsechange/stabilization of TcdB that prevents autoactivation and
receptor binding to target cells.
Phloretin Is a Direct Noncompetitive Inhibitor of Toxin
GTD Activity
A novel hit from the primary screen that was of considerable
interest was the naturally occurring flavonoid phloretin, which
protected cells from both TcdA- and TcdB-induced cell rounding
(Figure 4A). We discovered through subsequent characterization
that phloretin was a direct inhibitor of the toxin GTD domain, as it
dose dependently inhibited glucosylation of GST-Rac1 using the
in vitro Western blot assay (Figure 4B). To explore the mode of
inhibition further, we designed a novel scintillation proximity
assay (SPA) of glucosyltransferase activity using 3H-labeled
UDP-glucose to monitor GST-Rac1 glucosylation. In parallel,
we used a bioluminescent UDP detection assay (Promega) to
monitor UDP-glucose hydrolysis by the GTD in the absence of
GST-Rac1. Using these assays, we showed that phloretin dose
dependently inhibited both transferase and hydrolase activities
of the isolated GTD, albeit with differential potency, having IC50
values of 2.1 and 207.1 mM, respectively (Figure 4C).
Kinetic analysis of the inhibition of hydrolase activity by phlor-
etin demonstrated a marked reduction in reaction maximal
velocity (Vmax), while having no effect on the Km with respect to
UDP-glucose (Figure 4D). This kinetic pattern is a hallmark of a
noncompetitive mode of inhibition. This is well illustrated by
the Hanes-Woolf transformation, where the x intercept repre-
sents Km and 1/Vmax represents the slope of the line. For a
noncompetitive inhibitor, lines on a Hanes-Woolf plot will
converge on the x axis, as observed for phloretin (Figure 4D).
A closer look at the primary screening results as a whole
revealed the presence of additional phloretin-like analogs,
some of which were just below the hit cutoff line and others
that were inactive. Encouraged by the potential to identify addi-
tional and potentially more potent noncompetitive analogs of
phloretin, we screened a focused library containing 500 natural
and synthetic flavonoid derivatives using the cell-rounding
phenotypic assay (Figure S3). We identified two compounds of
particular interest: a chalcone derivative of phloretin called
ST031321 (Figure 4E), which partially protected cells from cell
rounding, and a more potent synthetic flavan analog of phloretin
called ST075672, which completely protected cells from TcdA-
and TcdB-induced rounding (Figure 4F). ST075672 was found
to inhibit both glucosyltransferase and hydrolase activity with
an IC50 of 7.7 and 38.9 mM, respectively.
Mechanism-Specific Inhibition of TcdB-Induced
Necrosis
At higher doses of TcdB, cells undergo a rapid necrotic-like cell
death via an NADPH oxidase pathway, characterized by a rapid
depletion of ATP, loss of membrane integrity, lack of caspase-3/
7 activation, and rapid lactate dehydrogenase release (Farrow
et al., 2013). This alternative phenotype was recently shown to
require a pore formation competent delivery domain (Zhang
et al., 2014) but not GTD or CPD activities (Chumbler et al.,
2012), suggesting that the host and toxin factors responsible
for mediating cell rounding and cellular necrosis, although over-
lapping, are distinct. Using the mechanistically distinct inhibitors
that were uncovered here, we asked whether and to what extentvier Ltd All rights reserved
Figure 3. Methyl Cholate Selectively Stabilizes TcdB and Inhibits Autoprocessing and Receptor Binding
(A) Structure of methyl cholate identified in the primary screen. In total, there were 12 cholate analogs in the primary screen, as shown in the bar graph below.
Analogs tested in the primary screen are shown below.
(B) (Top) Dose titration ofmethyl cholate on IMR-90 cells treatedwith either TcdA (red) or TcdB (blue). (Bottom) Dose titration of cholic acid on IMR-90 cells treated
with either TcdA (red) or TcdB (blue).
(C) Temperature-dependent fluorescence measurements of TcdBmelting temperature (Tm) in the presence of increasing concentrations of methyl cholate (black
squares) or cholic acid (gray open circles). Values represent the mean ± SD from three independent experiments.
(D) Western blot assay using Mab102 to detect TcdB glucosyltransferase activity. The Rac1 band detected in the absence of GTD loses reactivity with Mab102
following toxin-induced glucosylation. Methyl cholate does not inhibit glucosyltransferase activity up to the highest dose tested (200 mM). The direct inhibitor of
glucosyltransferase activity, phloretin, discovered in this study (see Figure 4), was used as a positive control to show recovery of signal by small molecule in-
hibition of GTD.
(E) Inhibition of autoactivation of full-length toxin (top) or a truncated construct of GTD-CPD (bottom). The highest dose tested is 200 mM with 3-fold dilutions.
Methyl cholate dose dependently inhibits autoprocessing of full-length toxin.
(F) Binding of TcdB to Vero cells. Vero cells were incubated with TcdB (100 ng/ml) in the absence or presence of bezlotoxumab (1.4 mM), methyl cholate (40 mM), or
cholic acid (40 mM), as indicated. Binding of TcdB was assessed by preparing membrane fractions and immunoblotting against TcdB with bezlotoxumab or a
cadherin-specific antibody (loading control). The bar graph showsmembrane-bound TcdB as the percentage bound relative to control under different conditions.
Values represent the mean ± SD from two independent experiments.different targeting strategies inhibited TcdB-mediated necrosis.
The antimalarial drug quinacrine, which inhibits endosomal acid-
ification, was a robust inhibitor of TcdB-induced necrosis (Fig-
ure 5A), further reinforcing the importance of pore formation in
mediating the necrosis phenotype (Zhang et al., 2014). Interest-Chemistry & Biology 22, 175ingly, methyl cholate, which blocks both CPD autoactivation
and receptor binding, inhibited the CPD-independent necrosis
phenotype (Figure 5B), consistent with the notion that inhibition
of receptor binding is likely responsible for the observed neutral-
ization. Last, the noncompetitive inhibitor phloretin was unable–185, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 179
Figure 4. Phloretin Is a Noncompetitive Inhibitor of TcdB Glucosyltransferase Activity
Biochemical characterization of GTD inhibitors.
(A) The structure of phloretin and its protective effects in the cell-rounding assay against TcdB (blue squares) and TcdA (red triangles).
(B) Western blot assay using Mab102 to detect TcdB glucosyltransferase activity. The Rac1 band detected in the absence of GTD loses reactivity with Mab102
following toxin-induced glucosylation. Phloretin dose dependently decreases glucosylation.
(C) Dose-dependent inhibition of GTD activity in the absence (hydrolase; open circles) and presence (transferase; filled circles) of GST-Rac1 using the UDP
detection and SPA assays, respectively. Results ± SEM are the average of three independent experiments.
(D) Kinetic analysis of GTD-associated hydrolase inhibition by phloretin. (Left) Reaction velocity plotted against substrate concentration and fit to the Michaelis-
Menten equation showing a decrease in Vmax and constant Km. (Right) A Hanes-Woolf transformation illustrating the change in Vmax (slope) constant Km
(x intercept), as expected for a noncompetitive inhibitor.
(E) ST031321, a chalcone analog of phloretin from the TimTec flavonoid library, dose dependently protects cells from TcdA and TcdB, albeit only partially.
(F) The synthetic flavan ST075762 dose dependently and completely protects cells from TcdA and TcdB (left) and inhibits both transferase and hydrolase
activities (right). Results ± SEM are the average of three independent experiments.to inhibit TcdB-induced necrosis, as would be expected for a
pure inhibitor of the GTD (Figure 5C).
DISCUSSION
Antibiotic resistance is eroding the efficacy of front-line agents
used to treat and control many infectious diseases. Along with
continuing to search for new antibiotics, there is a pressing
need to identify agents that inhibit bacterial pathogenesis in
different ways, such as by targeting the resistance mechanisms
directly (King et al., 2014; Leigh et al., 1981), or by inhibiting the
virulence factors that pathogens use to establish infection and
mediate disease (Cathcart et al., 2009; Hung et al., 2005; Lyon180 Chemistry & Biology 22, 175–185, February 19, 2015 ª2015 Elseet al., 2000). For CDIs where antibiotics are a major contributing
factor leading to disease and toxins are the primary determinants
of disease, the rationale for developing toxin-targeted therapies
is clear. Indeed, a number of large molecule toxin-neutralizing
approaches for CDI are being explored in the clinic, including
injectable monoclonal antibodies (Lowy et al., 2010) (in phase
3 for prevention of CDI recurrence) and toxoid vaccines (Foglia
et al., 2012) (entering phase 3 for prevention of first episode of
CDI). There remains a significant unmet need, however, for orally
bioavailable inhibitors of toxin action (i.e., small molecules) as a
safe and convenient therapeutic option for patients with mild to
severe toxigenic CDI. Importantly, in contrast with biologics-
based antitoxin candidates, which act exclusively by blockingvier Ltd All rights reserved
Figure 5. Mechanism-Based Inhibition of TcdB-Induced Necrosis
(A–C) TcdB induces a necrosis-like phenotype at high doses (Chumbler et al.,
2012) (i.e., >100 pM), as detected by a luminescent indicator CellTiter-Glo. We
measured inhibition of IMR-90 cells treated with 1,000 pM TcdB, corre-
sponding to the EC99 for (A) quinacrine (a representative inhibitor of endosomal
acidification), (B) methyl cholate, the inhibitor of receptor binding, and (C)
phloretin, the noncompetitive glucosyltransferase inhibitor. Experiments were
repeated three times, with representative curves shown.the initial binding to target cells, small molecules provide an op-
portunity to probe a greater array of toxin and host factors known
to be essential for TcdA and TcdB intoxication (Figure 1A).
In this study, we used a phenotypic screening approach to
identify the first generation of small molecules that protect cells
from the potent glucosylating toxins from C. difficile. We identi-
fied a structurally diverse set of compounds that protected cells
from TcdB-induced cell rounding through correspondingly
diverse sets of mechanisms. As with any such phenotypic
screening follow-up cascade, elucidating the precise mecha-
nism of action required the development of several specific
and general assays that flag spurious promiscuous binders.Chemistry & Biology 22, 175This was exemplified by the two natural trihydroxyphenyl com-
pounds from tea that have been linked to a number of health
benefits through their interactions with various protein targets
(Mori et al., 2010; Palhano et al., 2013; Rambold et al., 2008).
Autooxidation of the gallyl and gallate moieties within EGCG
and TG can create reactive species that react with cysteine thiol
groups (Ishii et al., 2008) and/or free amines in proteins (Palhano
et al., 2013). We saw evidence of this on SDS-PAGE and found
that the binding of these compounds was promiscuous, further
limiting their value as leads or as tool compounds.
A remarkable and essential feature of many bacterial toxins
is their capacity to undergo major conformational changes in
response to acidic pH that enable pore formation and transloca-
tion into the cytosol. Agents that prevent endosome-lysosome
acidification, such as the v-ATPase inhibitor bafilomycin A1 or
the lysosomotropic weak base ammonium chloride conse-
quently prevent these conformational steps that lead to intoxica-
tion (Qa’Dan et al., 2000). Here, we identified a number of
compounds that inhibited endosomal acidification, including a
set of antimalarial compounds and the antihypertensive drug
prazosin. Although known to be a highly effective means to
neutralize pH-dependent toxins in vitro (Gillespie et al., 2013;
Slater et al., 2013; Stechmann et al., 2010), it remains to be
addressed clinically whether a mechanism-based endosomal
modifier can be developed with a suitable therapeutic window
clinically. Nevertheless, the efficacy of these compounds on
both TcdB-induced cell rounding and necrosis provides oppor-
tunities to use these compounds and their derivatives to probe
specific aspects of toxin pathogenesis in vitro and potentially
in vivo.
Phenotypic screening studies aimed at identifying small mole-
cule inhibitors against other toxins, such as ricin, shiga-like toxin,
and anthrax, have identified molecules that largely targeted host
factors and processes (Gillespie et al., 2013; Slater et al., 2013;
Stechmann et al., 2010). In this study, we identified two distinct
direct inhibitors of toxin action. Our initial assignment of the
mechanism of the bile acid derivative methyl cholate as a CPD
inhibitor was puzzling. Finding a CPD inhibitor that protected
cells from TcdB was unexpected given the reported modest
impact that inactivating the CPD had on toxin potency
(Li et al., 2013; Olling et al., 2012). Subsequent characterization
of methyl cholate, however, revealed several important findings
that argue that CPD inhibition is indirect and likely not respon-
sible for the effects seen on cells. Chief among these was the
observed robust inhibition of receptor binding by methyl cholate
to levels similar to the neutralizing monoclonal antibody bezlo-
toxumab (Orth et al., 2014). That methyl cholate was unable to
inhibit a truncated construct containing GTD-CPD combined
with the observed inhibition of the CPD-independent necrosis
phenotype further indicates that inhibition of receptor binding
was responsible for the observed cellular protection. Another
interesting aspect of methyl cholate was the apparent selectivity
over TcdA. Future structural studies aimed at determining the
precise binding site on TcdB and how this binding affects CPD
activity, and more importantly receptor binding, are needed to
elucidate the detailed molecular mechanism of inhibition.
The second toxin-targeted compound discovered in this study
was the naturally occurring flavonoid phloretin. In contrast with
methyl cholate, phloretin inhibited both TcdB and TcdA with–185, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 181
approximately equal efficacy. The discovery that phloretin in-
hibited GTD activity using the low-throughput, semiquantitative
Western blot assay prompted us to use alternative approaches
that were more amenable to kinetic characterization to uncover
the mode of inhibition. Using assays of glucosyltransferase and
hydrolase activity, we discovered that phloretin was a noncom-
petitive inhibitor of the GTD. Although not anticipated, this may
reflect that the high intracellular UDP-glucose levels in cells
that may disfavor inhibitors are competitive with UDP-glucose.
An important feature of noncompetitive enzyme inhibitors is
that they can, in principle, achieve high selectivity over other
enzymes that utilize the same substrate or reaction mechanism.
Given the large number of human enzymes using UDP-glucose
as a substrate, this may be a critical factor for enabling selectivity
and safety of such inhibitors in the future. The lack of inhibition
of necrosis (as would be expected for a GTD inhibitor) also points
to future experiments aimed at pharmacological validation of the
importance of these distinct phenotypes in vivo.
While the mechanisms described herein await future in vivo
characterization for validation, these first-generation inhibitors
and their mechanisms nevertheless provide a wealth of informa-
tion regarding the pathogenesis and future treatment of CDI. In
particular, the compounds described herein offer an opportunity
to probe the relative importance of the two distinct phenotypes
pharmacologically in an in vivo setting.
SIGNIFICANCE
C. difficile is now the leading cause of antibiotic-associated
infection in hospitals worldwide. Pathogenic strains pro-
duce two homologous toxins, TcdA and TcdB, which cause
damage to the cells lining the colon, leading to fluid secre-
tion, tissue damage, and in some cases death. Recently,
more virulent strains of C. difficile have emerged character-
ized by greater antibiotic resistance and increased toxin
secretion, leading to a rise in the incidence and severity of
disease. In this study, we discovered small molecules
capable of protecting human cells from toxin damage. These
molecules and the mechanisms by which they act form the
foundation for developing the first generation of safe and
effective therapies to prevent the devastating effects of
toxins in patients suffering from infection.
EXPERIMENTAL PROCEDURES
Cell Lines, Consumables, and Reagents
Plasticware used for cell culture and enzyme assays was purchased from
Corning. Streptavidin Hi-bind plates, Superblock buffer, SuperSignal West,
and Quantablu peroxidase substrate were purchased from Thermo Pierce.
Cell lines CHO-k1, Vero, and IMR-90 were from ATCC. Anti-Rac1 antibody
Mab102 was from BD Biosciences, and anti-GST antibody was from Gen-
script. Anti-mouse conjugated peroxidase antibody was from GE Healthcare.
The Spectrum library, consisting of 2,320 individual compounds formatted as
10 mM solutions in DMSO, was purchased from MicroSource. The Flav500
(TimTec library) was purchased from Sigma-Aldrich.
Protein Expression and Purification
PlasmidpHis1522encodinghis-taggedTcdBwasakindgift fromHanpingFeng;
expression and isolation of recombinant TcdB was as described by Yang et al.
(2008). Briefly, transformedBacillusmegateriumwas inoculated into LBcontain-
ing tetracycline andgrown to anA600of 0.7, followedbyovernight xylose induc-182 Chemistry & Biology 22, 175–185, February 19, 2015 ª2015 Elsetion at 37C. Bacterial pellets were collected, resuspended with 20 mM Tris
(pH 8)/0.5 M NaCl, and passed twice through an EmulsiFlex C3 microfluidizer
(Avestin) at 15,000 psi, then clarified by centrifuging for 18,000 3 g for 20 min.
TcdBwaspurifiedbynickelaffinity chromatography followedbyanionexchange
chromatography using HisTrap FF and HiTrap Q columns (GE Healthcare),
respectively. Fractions containing TcdB were verified by SDS-PAGE, then
pooled and diafiltered with a 100,000 MWCO ultrafiltration device (Corning)
into 20 mM Tris (pH 7.5)/150 mM NaCl. Finally, glycerol was added to
15% v/v, the protein concentration was estimated by A280 (using coefficient
288160), divided into single use aliquots, and stored at 80C.
The regions encoding TcdB A (glucosyltransferase) and AC (glucosyl-
transferase + cysteine protease) domains were cloned into pET28 vectors
and expressed as His-tagged proteins in Escherichia coli BL21 DE3. Induction
of expression was initiated with 0.5 mM isopropyl b-d-1-thiogalactopyrano-
side (IPTG) for 3 hr. Cell lysates were prepared as described for full-length
TcdB, and purification of the protein was by nickel affinity chromatography
using HisTrap FF columns.
The pGEX-Rac1 plasmid (Addgene plasmid 12200) for expression of GST-
Rac1 protein was previously described by Bagrodia et al. (1995) and obtained
from Addgene. The plasmid was transformed into E. coli BL21 DE3, and re-
combinant protein expression was achieved by induction of the culture with
0.1 mM IPTG for 5 hr at 30C. The cell pellet was recovered by centrifugation,
resuspended with 5 ml/g of pellet in 20 mM Tris (pH 7.5)/150 mM NaCl,
and sonicated. The cell lysate was clarified by centrifugation, and the GST
fusion protein was purified by chromatography through a GSTrap Fast Flow
column (GE Healthcare). Following elution with 10 mM glutathione, fractions
containing purified protein were pooled and stored at –80C in the presence
of 15% v/v glycerol.
ArrayScan High-Content Phenotypic Screen
IMR-90 cells were grown in EMEM (Wisent) supplemented with 10% FBS
and penicillin-streptomycin (complete EMEM) and were seeded in 96-well
CellBIND plates (Corning) at a density of 8,000–10,000 cells/well. The next
day, the medium was exchanged with serum-free EMEM (SFM) containing
1 mM CellTracker Orange CMRA (Molecular Probes). After 60 min, excess
dye was removed by medium exchange with SFM. An Agilent Bravo liquid
handler was used to deliver 0.4 ml of compound from the MicroSource library
plate to the cell plate, immediately followed by 10 ml of 100 pM TcdB (diluted
in SFM) to a final volume of 100 ml, representing a concentration of toxin
previously established as EC99 levels of cytopathology. The cell plates
were returned to the incubator for 3.5 hr before imaging. CellTracker-labeled
cells were evaluated on a Cellomics ArrayScan VTI HCS reader (Thermo Sci-
entific) using the target acquisition mode, a 10x objective, and a sample rate
of 100 objects per well. After recording all image data, the cell rounding and
shrinking effects of TcdB intoxication were calculated using the CRI, a com-
bined measure of the LWR and area parameters. The % inhibition was calcu-
lated as the ratio between the sample well and the average toxin-untreated
controls after subtracting the average DMSO control values. The Z0 value
was calculated using the equation Z0 = 1  [(3sf + 3sb)/(mb  mf)], where s is
the SD, m is the average, f indicates the DMSO control, and b indicates the
toxin-untreated control. Wells that displayed potential suppression of toxin
activity (>39%) were verified by visual inspection to immediately exclude false
hits arising from cellular toxicity, precipitation, or autofluorescence/quenching.
Hits for confirmation and follow-up assays were ordered from Microsource
and Sigma as lyophilized powders. Dose-response curves were created and
evaluated using Prism software (GraphPad Software).
Acute Toxicity Assay
Loss of cellular ATP as a marker of high-dose (1 nM) TcdB toxicity was
measured as described for the ArrayScan screen protocol, except that
CellTiter-Glo reagent (Promega) was added to the cells 3 hr post toxin chal-
lenge, and luminescence was recorded on a SpectraMax M5 plate reader.
LysoTracker Assay
Endosomal pH neutralization was assayed essentially as described by
Slater et al. (2013); IMR-90 cells in complete EMEM were plated at 14,000
cells/well (95% confluency). After 24 hr, the medium was changed to SFM
for 60 min, then compound was added to 40 mM and incubated at 37C forvier Ltd All rights reserved
2 hr. LysoTracker red DND-99 and Hoechst (Life Technologies) were added to
0.1 mM and 1 mM, respectively, and incubated for 60 min. Excess dye was
removed by medium change, and the fluorescence at excitation/emission
574/594 was read on an Envision plate reader (Perkin Elmer). Representative
cell images were taken using a Zeiss Axiovert fluorescence microscope using
DAPI and Texas red filters to visualize the Hoechst and LysoTracker staining,
respectively.
Cysteine Protease Assay
Inhibition of TcdB self-cleavage by its intrinsic cysteine protease activity was
measured by preincubating test compounds with TcdB for 30 min, followed
by addition of InsP6, and incubating the reaction at 37C for 3 hr. Cleavage
was visualized by electrophoresing the samples on SDS polyacrylamide gels
and staining with Coomassie blue R250.
TcdB Aggregation and Cysteine Protease Activation Assay
Recombinant full-length TcdB in PBS/5 mM DTT was mixed with 50 mM com-
pound and incubated for 3 hr at room temperature. The samples were then
centrifuged at 10,000 3 g for 10 min before mixing the supernatant with an
equal volume of Laemmli sample buffer, electrophoresed on 4%–20% SDS
polyacrylamide gels, and stained with Coomassie R250.
Glucosyltransferase Western Blot Assays
For each reaction containing 10 nM GTD and 25 mMUDP-glucose, compound
was added (1% final DMSO) and preincubated for 30min, followed by addition
of gstRac1 to 0.8 mM. The reaction was stopped after a 60 min reaction time
with an equal volume of Laemmli loading buffer plus b-mercaptoethanol
(Bio-Rad), heated to 90C before immediately loading on an SDS polyacryl-
amide gel. Following electrophoresis, samples were transferred to nitrocellu-
lose using an iBlot device (Invitrogen), blocked with 5% milk/Tris-buffered
saline (TBS), and probed with a 1/1,000 dilution of either Mab102 or anti-
GST antibodies. Following an overnight incubation with the primary antibody,
the blot was washed with TBS/0.1% Tween20 and incubated with a 1/5,000
dilution of anti-mouse horseradish peroxidase for 60 min. After the final
washes in Tris-buffered saline with Tween 20, chemiluminescent detection
was carried out using SuperSignal substrate (Thermo Pierce) and exposing
to BioMax MR film (Kodak).
Differential Scanning Fluorometry
Differential scanning fluorometry was performed in a similar manner as
described previously (Niesen et al., 2007). TcdB protein was diluted in phos-
phate buffer (100 mM KPO4, 150 mM NaCl [pH 7]) containing 5x SYPRO
Orange (Invitrogen) and a serial dilution of test compound. A Bio-Rad CFX96
qRT-PCR thermocycler was used to establish a temperature gradient from
15C to 95C in 30 s increments, while simultaneously recording the increase
in SYPRO Orange fluorescence as a consequence of binding to hydrophobic
regions exposed on unfolded proteins. The Bio-Rad CFX Manager 3.1 soft-
ware was used to integrate the fluorescence curves to calculate the melting
point.
TcdB Cell Surface Binding
TcdB binding to Vero cells was assessed as described earlier with minor
modifications (Orth et al., 2014). Briefly, 100 ng/ml TcdB was preincubated
with 200 mg/ml bezlotoxumab, 40 mM methyl cholate, or 40 mM cholic acid
for 45 min in Eagle’s MEM supplemented with 10% FBS, 100 U/ml penicillin,
and 100 U/ml streptomycin. Mixtures were then added to confluent cultures
of prechilled Vero cells and plates were incubated on ice for 45 min. Plates
were thenwashed three timeswith cold PBS and harvested by scraping.Mem-
branes were isolated and samples analyzed by Western blot as previously
described (Orth et al., 2014).
SPA
The TcdB GTD was incubated at a final concentration of 2 nM in glucosylation
buffer (50 mM HEPES [pH 7.5], 100 mM KCl, 4 mM MgCl2, 1 mM MnCl2) with
various concentrations of inhibitor in a final volume of 20 ml in a 96-well PCR
plate (Sarstedt). Reactions were started with the simultaneous addition of
2.5 ml each of GST-Rac1 (20 mM final) and a mixture of 0.5 mCi of UDP-
[6-3H]-glucose (0.5 mM final) and cold UDP-glucose (19.5 mM final). ReactionsChemistry & Biology 22, 175were allowed to proceed at room temperature for 30 min, before being trans-
ferred to a white, polystyrene 96-well plate (Costar) containing a mixture
of 250 ml of 0.5 M EDTA and glutathione-coated polyvinyltoluene beads
(PerkinElmer) at a final concentration of 2 mg/ml. The beads were allowed to
settle overnight at room temperature to increase the signal to background ratio
before being analyzed on a TopCount NXT scintillation counter (PerkinElmer).
Results were analyzed using GraphPad Prism 5.0.
UDP-Glo UDP-Glucose Hydrolase Assay (Promega)
Experiments were performed as per the manufacturer’s instructions. Briefly,
100 nM of GTD enzyme was incubated in glucosylation buffer (see above)
with various concentrations of inhibitor in a final volume of 16 ml. Reactions
were started with the addition of 4 ml of UDP-glucose (50 mM final). Reactions
were allowed to proceed at room temperature for 15 min. To stop the reaction,
10 ml was removed and added to a white, polystyrene 96-well half-area plate
(Costar) containing 10 ml of UDP detection reagent. Plates were incubated at
room temperature for 1 hr, then luminescence was recorded on a SpectraMax
M5e plate reader (Molecular Devices) with an integration time of 750 ms.
Results were analyzed with SoftMax Pro 6.2.2 and GraphPad Prism 5.0.
Kinetic Measurements
The UDP-Glo assay was used to measure hydrolase activity as described
above at various concentrations of UDP-glucose (50, 25, 12.5, 6.25, 3.125,
and 1.56 mM) at various time points for 90 min, at various concentrations of
phloretin (60, 40, and 0 mM). Time courses were fit to the nonlinear function
[P] = v0/h(1  eht), where P is the product, v0 is the initial velocity, and h is
the relaxation constant of v0 that describes nonlinearity in progress curves
(Cao andDe LaCruz, 2013). Initial velocities were plotted against UDP-glucose
concentrations and fit to the Michaelis-Menten equation v = Vmax[S]/Km + [S],
to determine the kinetic constants Km and Vmax for each concentration of
phloretin.
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